Noema Pharma Raises CHF 103 Million (USD 112 Million) in Series B Financing Round Led by Forbion and Jeito Capital
The round was co-led by leading European healthcare focused investment firms Forbion and Jeito Capital.
- The round was co-led by leading European healthcare focused investment firms Forbion and Jeito Capital.
- Following the close of the Series B financing, Nanna Lüneborg from Forbion and Rachel Mears from Jeito Capital will join the Board of Directors of Noema Pharma.
- USD 60 million) Series A financing concluded in December 2020, led by Sofinnova Partners and Polaris Partners.
- Noema Pharma was founded in 2019 with a seed investment from Sofinnova Partners and four clinical stage assets in-licensed from Roche.